Manufacturing

Rethinking generics

Creating products that create greater efficiencies.

Alvogen is rethinking the way generics are brought to market. From our highly selective R&D strategy to our more rigorous manufacturing standards to our consolidated global supply chain, we're creating more meaningful ways to meet the needs of pharmacies and consumers.

rethinking_generics

North American
manufacturing facility

Alvogen’s future is built on the strong foundation of Alvogen’s Norwich, NY manufacturing site – a leading full-service pharmaceutical manufacturer with multi-dosage form capabilities for Rx and OTC products in the U.S., E.U. and international markets.

Located in Norwich, New York, with 8 billion unit total capacity, Alvogen’s Norwich, NY manufacturing site has long set the standard for service, quality and innovation – from introducing the first antiseptic surgical dressing to being the first to mass produce Pepto-Bismol to currently maintaining a 20-year compliance record without a single FDA-483 citation.

Alvogen is building on its Norwich, NY manufacturing site’s bedrock of proven reliability and ingenuity to provide you with the innovative products you need to drive efficiencies with the absolute assurances of quality, speed and supply.

Alvogen's Norwich, NY manufacturing site's development and manufacturing capabilities include:

 

  • 375,000 square-foot facility
  • 8 billion unit total capacity
  • Research and development laboratory
  • Pilot scale manufacturing suites
  • Commercial scale manufacturing suites
  • 20-year compliance record with no FDA-483 citations

Alvogen R&D center

Manufacturing

Cutting-edge research that yields customer-centric generics.

Located in Pine Brook, New Jersey, our cutting-edge research and development facility develops first-to-file and complex generic pharmaceutical products, including controlled release pharmaceuticals, that will be manufactured in our state-of-the-art U.S. manufacturing facility.

Staffed with multiple teams of seasoned professionals in both formulation and analytical chemistry, all with proven track records in filing and bringing to market first-to-file ANDAs, our R&D center strengthens our in-house development capabilities. These expanded internal capabilities form an important cornerstone of our targeted development strategy – a strategy designed to bring even more high-quality, low-cost generics to your shelves.

Connect with Alvogen Americas

Would you like to learn more about our portfolio, business development, or do you have an idea for partnership or future collaboration? We would like to hear from you.